UNI MEDICAL (02666) announced that on November 18, 2025 (after trading hours), the company, along with Zhongji Xineng (a wholly-owned indirect subsidiary of China General Technology Group) and Hele Technology, signed an agreement to establish a joint venture. According to the agreement, the joint venture will have a registered capital of RMB30 million, contributed in cash by the parties as follows: (i) UNI MEDICAL will invest RMB15.03 million, (ii) Zhongji Xineng will invest RMB4.47 million, and (iii) Hele Technology will invest RMB10.5 million. Upon establishment, the joint venture will be 50.1%, 14.9%, and 35% owned by UNI MEDICAL, Zhongji Xineng, and Hele Technology, respectively, and will become a subsidiary of UNI MEDICAL.
The joint venture aims to leverage preferential policies in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, including but not limited to fast-track approvals for clinically急需 imported medical devices under the "Nine National Measures," real-world data application pilots, and streamlined licensing for overseas medical practitioners. This initiative will facilitate the rapid registration, clinical application, and commercialization of innovative international medical devices in China.
Through collaboration with the pilot zone’s administrative bodies, medical institutions, and industry partners, the joint venture will establish a synergistic platform integrating policy alignment, technology transfer, and clinical validation. This will accelerate the introduction of cutting-edge global medical technologies into China while enhancing the efficiency of clinical translation and commercial value of innovations.
UNI MEDICAL believes this partnership aligns with China’s strategic focus on encouraging medical innovation and high-level openness, enriching its medical device business pipeline and creating long-term value for shareholders.
Comments